ES2163730T3 - Derivados espirocetales y su uso como agentes terapeuticos. - Google Patents

Derivados espirocetales y su uso como agentes terapeuticos.

Info

Publication number
ES2163730T3
ES2163730T3 ES97903437T ES97903437T ES2163730T3 ES 2163730 T3 ES2163730 T3 ES 2163730T3 ES 97903437 T ES97903437 T ES 97903437T ES 97903437 T ES97903437 T ES 97903437T ES 2163730 T3 ES2163730 T3 ES 2163730T3
Authority
ES
Spain
Prior art keywords
pct
spirocetal
derivatives
therapeutic agents
date aug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903437T
Other languages
English (en)
Inventor
Jason Matthew Elliott
Fintan Kelleher
Christopher John Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2163730T3 publication Critical patent/ES2163730T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), EN LA QUE R 1 , R 2 , R 4 , R 5 Y R 6 REPRESENTAN UNA VARIEDAD DE SUSTITUYENTES; R 3 REPRESE NTA UN GRUPO HETEROCICLICO AROMATICO DE 5 O 6 ELEMENTOS OPCIONALMENTE SUSTITUIDO QUE CONTIENE 1, 2, 3 O 4 HETEROATOMOS, SELECCIONADO DEL NITROGENO, OXIGENO Y AZUFRE. R 9A Y R 9B REPRESENTAN CADA UNO, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO C 1-4 , O R 9A Y R 9B ESTAN UNIDOS DE MODO QUE , JUNTO CON LOS ATOMOS DE CARBONO A LOS QUE ESTAN UNIDOS, FORMAN UN ANILLO C 5-7 ; M ES CERO, 1, 2 O 3; Y N ES CERO, 1, 2 O 3; CON LA CONDICION DE QUE LA SUMA TOTAL DE M Y N SEA 2O 3; O A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS. LOS COMPUESTOS SON DE USO PARTICULAR EN EL TRATAMIENTO O PREVENCION DEL DOLOR, INFLAMACIONES, MIGRAÑA, EMESIS Y NEURALGIA POSTHERPETICA.
ES97903437T 1996-02-15 1997-02-12 Derivados espirocetales y su uso como agentes terapeuticos. Expired - Lifetime ES2163730T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603137.2A GB9603137D0 (en) 1996-02-15 1996-02-15 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2163730T3 true ES2163730T3 (es) 2002-02-01

Family

ID=10788765

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903437T Expired - Lifetime ES2163730T3 (es) 1996-02-15 1997-02-12 Derivados espirocetales y su uso como agentes terapeuticos.

Country Status (9)

Country Link
US (1) US6127365A (es)
EP (1) EP0880528B1 (es)
JP (1) JP2000505442A (es)
AT (1) ATE206428T1 (es)
AU (1) AU716691B2 (es)
DE (1) DE69707104T2 (es)
ES (1) ES2163730T3 (es)
GB (1) GB9603137D0 (es)
WO (1) WO1997030055A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) * 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US6335364B1 (en) * 1998-06-29 2002-01-01 Parker Hughes Institute Synthetic spiroketal pyranes as potent anti-cancer agents
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
CA2509526A1 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
DE102007010077B4 (de) * 2007-02-28 2010-04-08 RUHR-UNIVERSITäT BOCHUM [1,3]-Dioxane zur Modulation von GABAa-Rezeptoren
MX2018004776A (es) 2015-10-23 2018-06-19 Esteve Labor Dr Compuestos oxaazaespiricos con actividad contral el dolor.
US11425169B2 (en) 2016-03-11 2022-08-23 Netskope, Inc. Small-footprint endpoint data loss prevention (DLP)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
ES2119174T3 (es) * 1993-01-28 1998-10-01 Merck & Co Inc Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas.
DE69318854T2 (de) * 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
WO1994029309A1 (en) * 1993-06-07 1994-12-22 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9426103D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US6127365A (en) 2000-10-03
GB9603137D0 (en) 1996-04-17
EP0880528A1 (en) 1998-12-02
AU716691B2 (en) 2000-03-02
AU1799297A (en) 1997-09-02
ATE206428T1 (de) 2001-10-15
DE69707104T2 (de) 2002-06-20
EP0880528B1 (en) 2001-10-04
JP2000505442A (ja) 2000-05-09
DE69707104D1 (de) 2001-11-08
WO1997030055A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
ATE227722T1 (de) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
ES2120170T3 (es) Antagonistas azaciclicos gem-disustituidos de taquiquininas.
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
ATE247096T1 (de) Tetrahydropyranderivate und deren verwendung als therapeutische mittel
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
PA8447801A1 (es) Derivados del acido hexanoico
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
ATE207897T1 (de) Piperidinderivate als neurokininantagonisten
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
DE69735482D1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
ES2163730T3 (es) Derivados espirocetales y su uso como agentes terapeuticos.
DK1242410T3 (da) Nye forbindelser
BG105710A (en) 5ht1 antagonists for antidepressant therapy
TR199901395T2 (xx) Yeni karboksi ikameli siklik karboksamid t�revleri.
MX9603199A (es) Antagonistas de receptores a endotelina.
ES2089669T3 (es) Utilizacion de los derivados de isoquinolinona en el tratamiento de la hiperlipoproteinemia.
PL343848A1 (en) Novel benzimidazoles and benzoxazoles
SE9802207D0 (sv) Novel compounds
ECSP972326A (es) Derivados de espiro - piperidina y su uso como agentes terapeuticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 880528

Country of ref document: ES